QuidelOrtho Corp (QDEL) Q1 2027 Earnings Call

Concluded May 5, 2026

May 5, 2026 0 turns

Period: FY2027 Q1
Runtime: —
Sources: 2 artifacts

Slides 9 8-K

Executive readout · one minute

Call research workspace

Read the call alongside every captured source. slides, 8-K earnings release stay in one workspace.

2026 financial guidance 36 Cash flow and balance sheet 29 R&D pipeline and product launches 24 Respiratory business 20 Leadership transition 18 Cost savings and margin expansion 13

Management tone

Positive

Net tone +45 · moderate hedging

Grounding quotes

“we delivered on our 2025 commitments executing against the priorities we outlined strengthening our business expanding margins and driving solid growth across our portfolio”
“we've realigned our cost structure, strengthened execution rigor, and improved the way the organization operates day-to-day. To date, our actions have generated $140 million in cost savings, expanded adjusted EBITDA margins to the low 20s, and increased our financial flexibility”
“we did this while delivering strong growth in our labs business, supported by our recurring revenue business model”
“i don't think we can point to, you know, major step function growth there as a result of a single assay”

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Presentation 9 pages 8-K earnings release Filed May 5, 2026 Company webcastOpen the original investor-relations page

Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →